Celanese Secures Grant Award For Research On Contraceptive Technology

August 24, 2022 3:13 PM | 1 min read |

Celanese Corp CE has received a grant from the Bill & Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant.
CE expects the project to produce a functional prototype that meets all established project parameters within an 18-month timeframe.
Through this grant, Celanese will provide critical research and development activities to facilitate and accelerate access to long-acting contraceptive options.
"The project concept is based on our VitalDose® drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe," commented Laura Brand, VP of the Celanese medical and pharmaceutical business.
Price Action: CE shares are trading lower by 0.04% at $115.95 on the last check Wednesday.

Posted In: News Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.